YBX1 and acute myeloid leukemia: In line with the previous result, we also uncovered that YBX1 expression was significantly increased on BM‐MSCs treated with MV4‐11 and paediatric AML patient sEVs (Figure 4d,e), compared to healthy control sEVs.